PubMed 274. Preynat-Seauve O, Burkhard PR, Villard J, Zingg W, Ginovart N, Feki A, Dubois-Dauphin M, Hurst SA, Mauron A, Jaconi M, et al.: Pluripotent stem cells as new drugs?
The example of Parkinson’s disease. Int J Pharm 2009,381(2):113–121.PubMed 275. Burt RK, Loh Y, Cohen B, Stefoski D, Doramapimod clinical trial Balabanov R, Katsamakis G, Oyama Y, Russell EJ, Stern J, Muraro P, et al.: Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009,8(3):244–253.PubMed 276. Crop MJ, Baan CC, Korevaar SS, Ijzermans JN, Alwayn IP, Weimar W, Hoogduijn MJ: Donor-derived mesenchymal stem cells suppress alloreactivity of kidney transplant patients. Transplantation 2009,87(6):896–906.PubMed 277. Troeger A, Meisel R, Moritz T, Dilloo D: Immunotherapy in allogeneic hematopoietic stem cell transplantation–not
just a case for effector cells. Bone Marrow Transplant 2005,35(Suppl 1):S59–64.PubMed 278. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, et al.: Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008,371(9624):1579–1586.PubMed find more 279. Iyer SS, Co C, Rojas M: Mesenchymal stem cells and inflammatory lung diseases. Panminerva Med 2009,51(1):5–16.PubMed 280. Nasef A, Ashammakhi N, Fouillard L: Immunomodulatory effect of mesenchymal stromal cells: possible mechanisms. Regen Med 2008,3(4):531–546.PubMed 281. Yamanaka S: A fresh look at iPS cells. Cell 2009,137(1):13–17.PubMed 282. Zhou H, Wu S, Joo JY, Zhu S, Han DW, Lin T, Trauger S, Bien G, Yao S, Zhu Y, et al.: Generation of induced pluripotent stem cells using recombinant proteins. Cell Stem Cell 2009,4(5):381–384.PubMed 283. Yamashita JK: ES and iPS cell research for cardiovascular regeneration. Exp Cell Res 2010,316(16):2555–2559.PubMed 284. Foster KW, Liu Z, Nail CD, Li X, Fitzgerald TJ, Bailey SK, Frost AR, Louro ID, Townes TM, Paterson AJ, et al.: Induction of KLF4 in basal keratinocytes blocks the proliferation-differentiation switch and initiates squamous epithelial dysplasia. Oncogene
EGFR inhibitor 2005,24(9):1491–1500.PubMed 285. Hochedlinger K, Yamada Y, Beard C, Jaenisch R: Ectopic expression of Oct-4 blocks selleck screening library progenitor-cell differentiation and causes dysplasia in epithelial tissues. Cell 2005,121(3):465–477.PubMed 286. Nair V: Retrovirus-induced oncogenesis and safety of retroviral vectors. Curr Opin Mol Ther 2008,10(5):431–438.PubMed 287. Soldner F, Hockemeyer D, Beard C, Gao Q, Bell GW, Cook EG, Hargus G, Blak A, Cooper O, Mitalipova M, et al.: Parkinson’s disease patient-derived induced pluripotent stem cells free of viral reprogramming factors. Cell 2009,136(5):964–977.PubMed 288. Maherali N, Hochedlinger K: Guidelines and techniques for the generation of induced pluripotent stem cells. Cell Stem Cell 2008,3(6):595–605.PubMed 289.